Scientists have mapped the genetics of cancer in cats for the first time at scale, uncovering major overlaps with human ...

(NASDAQ:IBRX) is one of the most buzzing stocks to buy with the highest upside potential. On March 9, ImmunityBio announced ...

Explore the latest colorectal cancer treatment advances, from precision oncology and immunotherapy to ADCs, bispecifics, and ...

The 2026 European Lung Cancer Congress (ELCC) will be held in Copenhagen, Denmark, from March 25 to 28, 2026 (local time). At ...

A guide to Medicare coverage for breast cancer diagnosis and treatment, including cost differences between Original Medicare ...

The FDA is approving a generic drug for a very rare genetic disorder, but not for autism. On Tuesday, the U.S. agency said ...

Meagan Johnson recently spent four days calling dozens of pharmacies around Austin, Texas, trying to fill a prescription for ...

Pharmacy benefit managers (PBMs) have used market leverage to demand rebates, which can lead drug manufacturers to increase ...

Pharmacists have urged Wes Streeting to stockpile medicines that may run out because of Iran’s blockade on the Strait of ...

Incyte INCY recently announced that the European Commission has approved a label expansion of oncology drug Zynyz ...

Last year, President Donald Trump told pregnant women not to take Tylenol as he promoted unproven ties between the fever ...

Merck & Co., Inc. (NYSE:MRK) has been on a strong recovery run, gaining 23% over the past year and 8% year-to-date, though the stock has pulled back some, now well below its 52-week high of $125.14.